Abstract
Saquinavir boosted with low-dose ritonavir given with zidovudine and lamivudine was well tolerated by pregnant women and their infants. All mothers had <400 human immunodeficiency virus type 1 RNA copies/ml at delivery. Two had elevated liver transaminases and amylase. Seven infant adverse events were possibly treatment related (anemia, neutropenia, and hyperbilirubinemia).
Publication types
-
Research Support, N.I.H., Extramural
MeSH terms
-
Anti-HIV Agents* / administration & dosage
-
Anti-HIV Agents* / adverse effects
-
Anti-HIV Agents* / therapeutic use
-
Drug Therapy, Combination
-
Female
-
HIV Infections / drug therapy*
-
HIV Infections / virology
-
HIV-1 / drug effects
-
Humans
-
Infant
-
Infant, Newborn
-
Infectious Disease Transmission, Vertical / prevention & control
-
Microbial Sensitivity Tests
-
Mothers
-
Pregnancy
-
Pregnancy Complications, Infectious / drug therapy*
-
Pregnancy Complications, Infectious / virology
-
RNA, Viral / blood
-
Reverse Transcriptase Inhibitors* / administration & dosage
-
Reverse Transcriptase Inhibitors* / adverse effects
-
Reverse Transcriptase Inhibitors* / therapeutic use
-
Ritonavir* / administration & dosage
-
Ritonavir* / adverse effects
-
Ritonavir* / therapeutic use
-
Saquinavir* / administration & dosage
-
Saquinavir* / adverse effects
-
Saquinavir* / therapeutic use
-
Treatment Outcome
Substances
-
Anti-HIV Agents
-
RNA, Viral
-
Reverse Transcriptase Inhibitors
-
Saquinavir
-
Ritonavir